Welcome to Erlend B. Smeland's group:
Lymphomas & Lymphocyte biology
The main focus of our research is to study B-cell lymphoma biology, and we perform molecular characterization as well as functional studies. Lymphomas are cancers derived from the cells of the immune system, and most often they arise from B-cells in the lymph nodes. By the means of high throughput analysis of gene expression and genomic and epigenetic alterations in lymphoma samples, we aim to elucidate oncogenetic mechanisms in lymphoma development. We also aim to identify prognostic markers and characterize biologically different subgroups of lymphoma.
We have a strong translational focus with a close collaboration with the lymphoma program in the Hospital and an extensive international collaboration. Several projects are connected to ongoing clinical trials, and we analyze primary patient samples using a broad spectrum of methods.
Selected lymphoma-specific genetic aberrations are followed up by basic cell biology research, using B cell lymphoma cell lines as models. Central techniques include studies of signalling pathways by Western blot analysis and multicolour flow cytometry, confocal microscopy, tissue micro array (TMA), array copy number genetic changes (aCGH), and gene expression profiling.
An overview of our key achievements can be found here.
The group is a member of Center for Cancer Biomedicine.
Molecular characterisation and studies of gene expression.
Epigenetic mechanisms in the development of malignant lymphoma
TGF-beta/BMP-induced signaling and functional effects in normal and malignant B-cells
High-throughput profiling of signaling pathways in B-cell lymphoma by Phospho-Flow cytometry
Lymphoma/Leukemia Molecular Profiling Project (LLMPP)
Department of Immunology, Institute for Cancer Research
The Norwegian Radium Hospital
0310 Oslo, Norway
|Phone:||+47 22 78 14 17 (Smeland)|
|+47 22 78 12 66 (Secretary)|
|+47 22 93 40 00 (switchboard)|
|Fax:||+47 22 78 13 45|
Email to E. Smeland: email@example.com
Early phase drug development: From idea to concept
Feb 3, 2017
Feb 2, 2017
Oncolytic peptide LTX-315; the road from basic science to clinical trials
Jan 26, 2017
Erlend B. Smeland's group
T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy
Oncoimmunology, 5 (12), e1249090
Mass Cytometry of Follicular Lymphoma Tumors Reveals Intrinsic Heterogeneity in Proteins Including HLA-DR and a Deficit in Nonmalignant Plasmablast and Germinal Center B-Cell Populations
Cytometry B Clin Cytom, 92 (1), 79-87